Granata Bio Corporation is accelerating progress in reproductive health. The company has now moved its pivotal Phase III study into active enrollment, marking a major step toward expanding fertility treatment options.
The GRACE Study is a multicenter, randomized, controlled Phase III trial. Its goal is simple: evaluate a new gonadotropin product for women undergoing IVF.
Key study objectives include:
The study is already enrolling patients across leading U.S. fertility centers.
Infertility treatments remain expensive, complex, and emotionally demanding. Reproductive endocrinologists see the impact daily.
Dr. John Park shared this perspective:
“Patients need more effective and affordable care. We are excited to join a study that could expand access for IVF patients.”
His statement reflects a core truth: more options create better outcomes.
The company’s gonadotropin program is rooted in innovation and practicality. It aims to improve access while maintaining quality and consistency.
Granata Bio is also advancing early-stage programs focused on novel biologics. These programs target long-term transformation in fertility medicine.
As Barbara Cometti, PhD, noted:
“This milestone highlights our commitment to innovation and real-world impact. We continue to pursue programs that can redefine reproductive care.”
Granata Bio is positioning itself as a catalyst in modern fertility science. Its strategy blends proven therapeutic classes with improved manufacturing and accessibility.
Patients, clinicians, and the broader reproductive health community now watch closely. The GRACE Study could reshape how gonadotropins are delivered and accessed.
To follow updates or explore participation, visit the GRACE Study website. This trial represents another step toward improving options for families seeking IVF support.